Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Novartis

Status and phase: Completed; Phase 4

Conditions: Hypertension; Left Ventricular Hypertrophy

Treatments: Drug: amlodipine/benazepril

Study type: Interventional

Funder types: Industry

Identifiers

NCT00139555

CCIB002FUS16

Details and patient eligibility

About

Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.

Enrollment: 125 patients

Sex: All

Ages: 55+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or female patients ≥ 55 years of age
• LVH as confirmed by echocardiogram
• Patients with high risk hypertension, currently treated or already taking antihypertensive medication

Exclusion criteria

• Renal artery stenosis
• Symptomatic heart failure or known ejection fraction < 40%
• Myocardial infarction or stroke within 6 months
• Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers
• Pregnant or lactating females
• Cancer within the last 5 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind